MedTrace Logo

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

NCT01617954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 820

Last updated 2016-01-29

No results posted yet for this study

Summary

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Conditions

  • Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DEVICE

MammaPrint

All subjects

Sponsors & Collaborators

  • Agendia

    lead INDUSTRY

Principal Investigators

  • Michaela Tsai, MD · Piper Breast Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01617954 on ClinicalTrials.gov